Search Results

Drug Development

HepaRegeniX publishes data for its first-in-class MKK4 inhibitor HRX-215 for the treatment of acute and chronic liver diseases in Cell

HepaRegeniX GmbH, a clinical stage company developing novel regenerative therapies for the treatment of acute and chronic liver diseases, today published clinical and preclinical results on its first-in-class MKK4 inhibitor HRX-215 in the prestigious journal Cell.

March 14, 2024

·

4 min read

Business

HepaRegeniX raises €15 million Series C round to advance clinical development of HRX-215 for liver regeneration

July 10, 2024

·

4 min read

Deals

Great Point Partners Acquires Lyocontract GmbH, Germany-Based Drug Product CDMO

Great Point Partners, a Greenwich-based investment firm focused exclusively on the health care industry, announced the acquisition of Lyocontract GmbH, a premium independent drug product contract development and manufacturing organization based in Ilsenburg, Germany.

June 13, 2024

·

3 min read

Business

Oakwood Chemical Announces Strategic Partnership with EMP Biotech GmbH

Oakwood Chemical is thrilled to unveil its collaboration with EMP Biotech GmbH, a move set to streamline the oligo synthesis supply chain.

April 9, 2024

·

2 min read

Press Releases

FGK Clinical Research GmbH Highlights 3.5 Years of Success with Flex Databases

October 10, 2024

·

1 min read

Drug Development

HD Immune GmbH Foundation and Publication of Latest Pre-Clinical Data

HD Immune GmbH announces commencement of operations by its two founders Dr. Stefan Bartl and Dr. Lionel Wightman.

January 23, 2024

·

2 min read

Press Releases

Dovetail Genomics and Goenomics GmbH Announce Strategic Partnership to Enhance Genome Annotation Services

August 21, 2024

·

4 min read

Business

HepaRegeniX Appoints Elias Papatheodorou as New Chairman of the Board of Directors

HepaRegeniX GmbH, a clinical stage company developing novel regenerative therapy approaches for the treatment of acute and chronic liver diseases, announced the appointment of Elias Papatheodorou as chairman of the board of directors with executive functions.

March 30, 2022

·

2 min read

Press Releases

BioNxt Signs Letter of Intent with Gen-Plus GmbH & Co KG for Potential Business Collaborations

August 15, 2024

·

3 min read

Business

UroGen Secures Exclusive License from medac GmbH to Develop a Next-Generation Novel Mitomycin-Based Formulation for Urothelial Cancers

UroGen Pharma Ltd. today announced a licensing agreement with medac GmbH to develop a next-generation novel mitomycin-based formulation for urothelial cancers.

January 17, 2024

·

6 min read